CNS Pharmaceuticals (NASDAQ:CNSP) Announces Quarterly Earnings Results

Posted by Geri Gentry on May 14th, 2026

CNS Pharmaceuticals (NASDAQ:CNSP – Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($7.30) earnings per share for the quarter, FiscalAI reports.

CNS Pharmaceuticals Trading Down 9.2%

Shares of NASDAQ CNSP traded down $0.51 during midday trading on Thursday, hitting $5.01. The company’s stock had a trading volume of 57,228 shares, compared to its average volume of 4,337,791. The business’s 50 day moving average is $3.14 and its two-hundred day moving average is $4.92. CNS Pharmaceuticals has a 12-month low of $1.90 and a 12-month high of $16.56. The firm has a market cap of $4.06 million, a P/E ratio of -0.12 and a beta of 2.62.

Institutional Investors Weigh In On CNS Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the business. Boothbay Fund Management LLC purchased a new stake in shares of CNS Pharmaceuticals in the fourth quarter worth approximately $71,000. Ikarian Capital LLC purchased a new stake in shares of CNS Pharmaceuticals in the fourth quarter worth approximately $241,000. Finally, Armistice Capital LLC purchased a new stake in shares of CNS Pharmaceuticals in the second quarter worth approximately $335,000. 14.02% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of CNS Pharmaceuticals in a report on Monday, April 20th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, CNS Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $20.00.

View Our Latest Research Report on CNSP

CNS Pharmaceuticals Company Profile

(Get Free Report)

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.